title: Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge.
abstract: The importance of neutralizing antibodies (NAbs) in protection against hepatitis C virus (HCV) remains controversial. We infused a chimpanzee with H06 immunoglobulin from a genotype 1a HCV-infected patient and challenged with genotype strains efficiently neutralized by H06 in vitro. Genotype 1a NAbs afforded no protection against genotype 4a or 5a. Protection against homologous 1a lasted 18 weeks, but infection emerged when NAb titers waned. However, 6a infection was prevented. The differential in vivo neutralization patterns have implications for HCV vaccine development.
authors.affiliation: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA jbukh@sund.ku.dk.
authors.forename: Jens
authors.initials: J
authors.lastname: Bukh
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Engle
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Kristina
authors.initials: K
authors.lastname: Faulk
authors.affiliation: Department of Transfusion Medicine, Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Richard Y
authors.initials: RY
authors.lastname: Wang
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Farci
authors.affiliation: Department of Transfusion Medicine, Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Harvey J
authors.initials: HJ
authors.lastname: Alter
authors.affiliation: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Purcell
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000627:therapeutic use*; D018420:Ape Diseases / Q000276:immunology / Q000517:prevention & control; D003429:Cross Reactions / Q000276:immunology; D005838:Genotype; D016174:Hepacivirus / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000276:immunology / Q000627:therapeutic use*; D002679:Pan troglodytes / Q000821:virology; D014761:Viral Hepatitis Vaccines / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D057134:Antibodies, Neutralizing; D018937:Hepatitis C Antibodies; D007136:Immunoglobulins; D014761:Viral Hepatitis Vaccines